Relapse of Birdshot Uveitis after Stopping Immunosuppressive Treatment and Starting Immune Checkpoint Inhibitors for Lung Cancer
A 56-year-old Caucasian woman with birdshot uveitis had to stop immunosuppressive treatment with adalimumab due to metastatic squamous lung carcinoma. She was subsequently treated with chemotherapy and pembrolizumab, an immune checkpoint inhibitor (ICI). After stopping adalimumab and starting pembrolizumab, the patient had an inflammatory relapse of birdshot uveitis with macular oedema. Birdshot uveitis is triggered by an unknown antigen presented on the HLA-A29 molecule which activates cytotoxic T-cells. Although immunosuppressive therapy effectively stabilizes birdshot uveitis, it might induce a higher risk of developing cancer. Treatment with ICIs, on the other hand, might exacerbate birdshot uveitis by increasing anti-tumoural immune reaction and inducing off-target autoimmunity.
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
Relapse of Birdshot Uveitis after Stopping Immunosuppressive Treatment and Starting Immune Checkpoint Inhibitors for Lung Cancer ; volume:13 ; number:3 ; year:2022 ; pages:901-906 ; extent:6
Case reports in ophthalmology ; 13, Heft 3 (2022), 901-906 (gesamt 6)
- Creator
-
Alsaddi, Mohammed A.M.
Hondeghem, Kathy
Schauwvlieghe, Pieter-Paul
- DOI
-
10.1159/000526636
- URN
-
urn:nbn:de:101:1-2023010423270618043233
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:28 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Alsaddi, Mohammed A.M.
- Hondeghem, Kathy
- Schauwvlieghe, Pieter-Paul
Other Objects (12)
Predictors of relapse after discontinuing systemic treatment in autoimmune chronic uveitis
Therapeutic Response After Immunosuppressive Drug Prescription in Non-infectious Uveitis: A Survival Analysis
Optimal Starting and Stopping Rules for Resource Depletion when Price is Exogenous and Stochastic
Step on it: asymmetric gain functions improve starting and stopping in virtual reality walking
Highly immunosuppressive myeloid cells correlate with early relapse after allogeneic stem cell transplantation
New-onset or relapse of uveitis after rapid spreading of COVID-19 infection in China and risk factor analysis for relapse
Conventional immunosuppressive therapy in severe Behcet’s Uveitis: the switch rate to the biological agents
Discontinuing adalimumab in patients with controlled juvenile idiopathic arthritis-associated uveitis (ADJUST—Adalimumab in Juvenile Idiopathic Arthritis-associated Uveitis Stopping Trial): study protocol for a randomised controlled trial
Optimal stopping rules
Stopping human trafficking
Stopping human trafficking
Stopping Microfluidic Flow
Predictors of relapse after discontinuing systemic treatment in autoimmune chronic uveitis
Therapeutic Response After Immunosuppressive Drug Prescription in Non-infectious Uveitis: A Survival Analysis
Optimal Starting and Stopping Rules for Resource Depletion when Price is Exogenous and Stochastic
Step on it: asymmetric gain functions improve starting and stopping in virtual reality walking
Highly immunosuppressive myeloid cells correlate with early relapse after allogeneic stem cell transplantation
New-onset or relapse of uveitis after rapid spreading of COVID-19 infection in China and risk factor analysis for relapse
Conventional immunosuppressive therapy in severe Behcet’s Uveitis: the switch rate to the biological agents
Discontinuing adalimumab in patients with controlled juvenile idiopathic arthritis-associated uveitis (ADJUST—Adalimumab in Juvenile Idiopathic Arthritis-associated Uveitis Stopping Trial): study protocol for a randomised controlled trial
Optimal stopping rules
Stopping human trafficking
Stopping human trafficking
Stopping Microfluidic Flow
Predictors of relapse after discontinuing systemic treatment in autoimmune chronic uveitis
Therapeutic Response After Immunosuppressive Drug Prescription in Non-infectious Uveitis: A Survival Analysis
Optimal Starting and Stopping Rules for Resource Depletion when Price is Exogenous and Stochastic
Step on it: asymmetric gain functions improve starting and stopping in virtual reality walking
Highly immunosuppressive myeloid cells correlate with early relapse after allogeneic stem cell transplantation
New-onset or relapse of uveitis after rapid spreading of COVID-19 infection in China and risk factor analysis for relapse
Conventional immunosuppressive therapy in severe Behcet’s Uveitis: the switch rate to the biological agents
Discontinuing adalimumab in patients with controlled juvenile idiopathic arthritis-associated uveitis (ADJUST—Adalimumab in Juvenile Idiopathic Arthritis-associated Uveitis Stopping Trial): study protocol for a randomised controlled trial
Optimal stopping rules
Stopping human trafficking
Stopping human trafficking